Development and pharmacological characterization of "caged" urotensin II analogs

Peptides. 2005 Aug;26(8):1475-80. doi: 10.1016/j.peptides.2005.03.019. Epub 2005 Apr 19.

Abstract

Urotensin-II (U-II) is a cyclic 11-amino acid peptide known as a potent mammalian vasoconstrictor. To study some purported intracellular actions of U-II, masked analogs of this peptide, becoming biologically active only upon UV exposure, were developed. Those analogs described as "caged" were derivatized with a photolabile 4,5-dimethoxynitrobenzyl group on the side chain of Lys-8 or Tyr-9. Both caged analogs of U-II showed a major decrease in their affinity towards the UT receptor. Nevertheless, upon UV irradiation, the native and biologically active U-II peptide was recovered. Thus, this work describes the development of new "caged" U-II derivatives and demonstrates that vasoactivity of U-II can be controlled by masking and unmasking two key residues.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Aorta, Thoracic / drug effects
  • Aorta, Thoracic / radiation effects
  • Humans
  • Kinetics
  • Male
  • Peptides, Cyclic / chemical synthesis
  • Peptides, Cyclic / pharmacology
  • Peptides, Cyclic / radiation effects
  • Photolysis / radiation effects
  • Rats
  • Rats, Sprague-Dawley
  • Time Factors
  • Ultraviolet Rays
  • Urotensins* / chemical synthesis
  • Urotensins* / pharmacology
  • Urotensins* / radiation effects

Substances

  • Peptides, Cyclic
  • Urotensins
  • urotensin II